Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world Adjuvant Octreotide in pNETs
NCT06080204Completed
- Sponsor
- Changhai Hospital
- Start
- Mar 2008
- Primary completion
- Apr 2020
- Modality
- Peptides
01
Overview
Open-label trial of Octreotide long-acting injection in Pancreatic neuroendocrine tumor (PanNET) (2 arms), sponsored by Changhai Hospital. Primary endpoint: Disease-free survival time at 120 months. Started Mar 2008; status: completed.
02
Drugs
Octreotide long-acting injection
03
Conditions
Pancreatic neuroendocrine tumor (PanNET)
Beyond the preview
Go deeper on NCT06080204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06080204.